Stroke Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Stroke Therapeutics Market Analysis
The stroke therapeutics market is projected to register a CAGR of 4.5% during the forecast period, 2022-2027.
Due to the presence of a huge stroke patient base across the world, there is a need for innovative and safe stroke treatment. Currently, only Tissue Plasminogen Activators (TPA) therapy is approved for stroke treatment. Additionally, surgery and removing clots by using a stent retriever are some of the other options available to recover from the stroke. Anti-platelets, anti-coagulants, and anti-convulsant are utilized for the further management of stroke. Covid-19 has significantly impacted the overall healthcare industry. Though it does not directly impact the stroke therapy market, however, there was a disruption in the supply chain of diagnostic & treatment devices and therapeutics. Additionally, many industry players reduced their investment in further development of innovative therapy due to financial losses during the Covid-19 period.
There is a huge population with high cholesterol, high blood pressure, obesity, diabetes, and cardiovascular diseases due to a sedentary lifestyle, and these are the key risk factors for stroke. According to data published by World Stroke Organization (WSO) in 2022, About 12 million (12,224,551) people experienced a stroke in 2019. The organization stated that there are more than 12.2 million new strokes each year, and globally, one in four people after 25 years of age experience a stroke in their lifetime. Hence, the increasing burden of patients globally is expected to drive market growth.
Patent expiry of branded drugs in recent years may impede the therapeutics market growth. For instance, Xarelto's (Rivaroxaban) US7585860 patent expired in December 2020, and the US7585860 patent is expected to expire by June 2022. Already, Breckenridge, Aurobindo, Hec Pharma, Invagen, Mylan, SigmaPharma, Microlabs, Torrent, Sun (Taro), Teva, Prinston Pharma, Alembic, Macleods, Lupin, and Accord (Intas) filed Abbreviated New Drug Application (ANDA) for the same drug. Hence, the entry of several generic is likely to increase pricing pressure on the market players, and this factor may hamper the market growth.
Stroke Therapeutics Market Trends
This section covers the major market trends shaping the Stroke Therapeutics Market according to our research experts:
Tissue Plasminogen Activators (TPA) Dominated in the Market and is Expected to Hold Dominance during the Forecast Period
Tissue plasminogen activator is an effective blood thinner and is approved for the treatment of stroke. It improves the chances of recovering. Several studies observed that patients who receive tissue plasminogen activator during their ischemic stroke are more likely to recover completely or have fewer chances of disability than those who do not consume the drug. Hence, for all patients with ischemic stroke, a tissue plasminogen activator is a first-line therapy to treat.
Activase and Tenecteplase are tissue plasminogen activators manufactured by using recombinant technology and hence named an r-tPA. Availability of products, investment by industry players for commercialization of products, and improving healthcare access in developing countries are some of the key factors driving the market growth. Additionally, several countries' stroke awareness programs support efforts to enhance the utilization of tissue plasminogen activators in eligible stroke patients and thereby improve the outcome of treatment. For instance, the National Institute of Neurological Disorders and Stroke (NINDS) launched a public awareness campaign in the U.S. in 2001 to assist people in recognizing the early signs and symptoms of a stroke. The institute also spreads awareness about the benefits of early treatment through tissue plasminogen activators. Such awareness and educational programs help to improve the utilization of tissue plasminogen activators among patients as soon as their symptoms start.
In January 2022, Thrombolytic Science, LLC was granted a second patent by the United States Patent and Trademark Office for the innovative treatment of ischemic stroke through the use of fibrinolytic enzymes, tissue plasminogen activator, tPA, and urokinase plasminogen activator, uPA. The recent patent approval will pave the way for the development of tissue plasminogen activator-based treatment of stroke, which will likely add to the market growth.
However, patent expiry and entry of Clot-retrieval devices are some of the factors that may restrain the tissue plasminogen activator market growth during the forecast period. For instance, several studies showed that clot retrieval devices are effective in treating clots in large arteries. However, a small artery tissue plasminogen activator is still a preferred treatment.
North America Held a Maximum Share in the Market and Expected to Dominate the Market during the Forecast Period
The United States contributed maximum in the North America region in 2021 and is responsible for the dominance of the region across the world. Advanced healthcare infrastructure, well-equipped hospitals, and availability of point of care services are responsible for the maximum demand of drugs for stroke from the United States. Stroke is a condition where treatment must be given as early as possible after the onset of symptoms and hence the availability of quick treatment is a key factor responsible for the high survival rate in the United States. According to the statistics published by the Centers for Disease Control and Prevention (CDC) in April 2022, more than 795,000 Americans have strokes. From which 610,000 are found to be new cases each year. Statistics also showed that Stroke is one of the leading causes of death in the United States and every 40 seconds, someone from the United States has a stroke. This huge patient base and ease in accessing advanced treatment are responsible for the major share of the region across the globe.
North America is expected to observe the same dominance during the forecast period due to development of innovative therapies, local presence of major industry players, and entry of new therapies. In November 2020, the United States Food and Drug Administration approved AstraZeneca's Brilinta to reduce further risk of stroke in an acute ischaemic stroke. The drug works by inhibiting platelet activation mechanism.
Stroke Therapeutics Industry Overview
The stroke therapeutics market is fragmented, competitive, and consists of several major players. Patent expiry of major drugs is responsible for the entry of several generic drugs into the market, and thereby competition in the market increases. AstraZeneca, Amgen Inc., Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Merck and Co. Inc., Johnson and Johnson Inc., Pfizer Inc., Sanofi SA, Daiichi Sankyo Company, Limited, and Biogen Inc. are some of the key operating players in the stroke therapeutics market.
Stroke Therapeutics Market Leaders
-
Bristol-Myers Squibb Company
-
Boehringer Ingelheim International GmbH
-
F. Hoffmann La Roche Ltd.
-
Johnson & Johnson
-
Pfizer Inc
*Disclaimer: Major Players sorted in no particular order
Stroke Therapeutics Market News
In May 2022, researchers at the Osaka Metropolitan University are studying robotic therapy as an effective therapy during the chronic stage of stroke recovery. If widely adopted, robot therapy could improve care for stroke patients while being cost-effective and requiring minimal therapeutic staff guidance.
In April 2022, the United States National Institute of Health funded a USD 1.8 million project to use artificially grown, simplified mini-organs to create medicine that targets brain cells damaged by stroke. The project focuses on the creation of brain-like miniature organs, from which the particles naturally released could be harvested for medicine production.
Stroke Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions & Market Defination
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Investment by Market Players for the Development of New Therapy and Advanced Technology
- 4.2.2 Increasing Number of Stroke Patients
-
4.3 Market Restraints
- 4.3.1 Entry of Various Generic Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Type
- 5.1.1 Ischemic Stroke
- 5.1.2 Hemorrhagic Stroke
-
5.2 By Treatment
- 5.2.1 Tissue Plasminogen Activators (TPA)
- 5.2.2 Anticoagulants
- 5.2.3 Antiplatelets
- 5.2.4 Others
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Clinics
- 5.3.3 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Amgen Inc.
- 6.1.2 Bristol-Myers Squibb Company
- 6.1.3 Bayer AG
- 6.1.4 Boehringer Ingelheim International GmbH
- 6.1.5 F. Hoffmann La Roche Ltd.
- 6.1.6 Merck and Co. Inc.
- 6.1.7 Pfizer Inc.
- 6.1.8 Sanofi SA
- 6.1.9 Daiichi Sankyo Company, Limited
- 6.1.10 Biogen Inc.
- 6.1.11 Johnson & Johnson
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityStroke Therapeutics Industry Segmentation
As per the scope of this report, stroke is a condition in which the supply of blood is reduced or blocked completely to the brain, and this is either due to clots or rupturing of the blood vessel in the brain. The stroke therapeutics market is segmented by Type (Ischemic Stroke, Hemorrhagic Stroke), By Treatment (Tissue Plasminogen Activators (TPA), Anticoagulants, Antiplatelets, Others), By End User (Hospitals, Clinics, Others), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.
| By Type | Ischemic Stroke | |
| Hemorrhagic Stroke | ||
| By Treatment | Tissue Plasminogen Activators (TPA) | |
| Anticoagulants | ||
| Antiplatelets | ||
| Others | ||
| By End User | Hospitals | |
| Clinics | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Stroke Therapeutics Market Research FAQs
What is the current Global Stroke Therapeutics Market size?
The Global Stroke Therapeutics Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)
Who are the key players in Global Stroke Therapeutics Market?
Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, F. Hoffmann La Roche Ltd., Johnson & Johnson and Pfizer Inc are the major companies operating in the Global Stroke Therapeutics Market.
Which is the fastest growing region in Global Stroke Therapeutics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Stroke Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Stroke Therapeutics Market.
What years does this Global Stroke Therapeutics Market cover?
The report covers the Global Stroke Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Stroke Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Stroke Industry Report
Statistics for the 2024 Stroke market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Stroke analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
